

ISPOR 47th Health Technology Assessment Roundtable

25 October 2019

8:00AM-12:00PM

Rome Ballroom, Marco Polo Parkside Beijing

Beijing, China

Delegates (21)

ISPOR Board of Directors (1)

Nancy Devlin, PhD, ISPOR President (2019-2020), and Director, Centre for Health Policy, University of Melbourne, Melbourne Victoria, Australia

Australia (1)

Kirsten Howard, MPH, PhD, Chair, Economic Sub-Committee of Pharmaceutical Benefits Advisory Committee, Department of Health, and Professor, Health Economics School of Public Health, The University of Sydney, Sydney, Australia

Bhutan (1)

Deepika Adhikari, Senior Program Officer, Essential Medicines and Technology Division, Department of Medical Services, Ministry of Health, Thimphu, Bhutan

China (6)

Kun Zhao, MD, PhD, Professor and Director, Division of Health Technology Assessment, China National Health Development Research Center, National Health Commission, Beijing, China

Jing Wu, PhD, Professor, Pharmaceutical Economics and Policy, Tianjin University, Tianjin, China

Kevin Huang, President and Founder, China Organization for Rare Disorders, Beijing, China

Lixin Wang, Secretary General, China Rare Disease Organizations Development Network, Tianjing, China

Hongfei Gu, Founder, Lymphoma Association of China (House 086), Beijing, China

Representative, Chinese Pharmaceutical Association, Beijing, China

India (1)

Oshima Sachin, Scientist-D, HTA In Secretariat, Department of Health Research, Ministry of Health and Family Welfare, New Delhi, India

Indonesia (1)

Sudigdo Sastroasmoro, MD, PhD, Chair of HTA Committee, Ministry of Health, Jakarta, Indonesia

Japan (2)

Takashi Fukuda, PhD, Director, Department of Health and Welfare Services, National Institute of Public Health, Saitama, Japan

Ruoyan Gai, MSc, PhD, Senior research officer, National Institute of Social Security and Population Research, Tokyo, Japan

Malaysia (1)

Roza binti Sarimin, Head of MaHTAS Monitoring and Evaluation Unit, Medical Development Division, Ministry of Health, Kuala Lumpur, Malaysia

Mongolia (1)

Ulzii-orshikh Khaltar, Officer for HTA, Department of Drug, Industry and Technology, Ministry of Health Ulaanbaatar, Mongolia

Philippines (1)

Abigail Estrada, BSN, Chief Social Insurance Specialist, Benefits Development and Research Department, Philippine Health Insurance Corporation, Pasig City, Philippines

Singapore (1)

Kwong Hoe Ng, Head, Evaluation and Appraisal, Agency for Care Effectiveness, Ministry of Health, and Adjunct Associate Professor, Saw Swee Hock School of Public Health, National University of Singapore, Singapore

South Korea (2)

Sukyeong Kim, PhD, Immediate Past Chair, ISPOR HTA Roundtable-Asia Pacific, and Senior Research Fellow, Evidence-based Research Department, National Evidence-based Health Care Collaborating Agency (NECA), Seoul, South Korea

Yoon Hee Choi, Manager, Pharmaceutical Listing Division, Pharmaceutical Benefit Department Health Insurance Review and Assessment Service (HIRA), Seoul, South Korea

Taiwan (1)

Churn-Shiouh Gau, PhD, Chief Executive Director, Center for Drug Evaluation (CDE), Taipei, Taiwan

Thailand (1)

Songyot Pilasant, MSc, Head of the Research Unit, Health Intervention and Technology Assessment Program (HITAP), Bangkok, Thailand

ISPOR Staff Members (2)

Robert Selby, Director, Global Networks – Asia Pacific and Latin America, ISPOR, Lawrenceville, NJ, USA

Nancy Chen, Associate Director and Content Strategist, Global Networks – Asia Pacific and Latin America, ISPOR, Lawrenceville, NJ, USA